MORE INSIGHTS IN LESS TIME
The world's first fully automated end-to-end solution for digital histopathology – ready for AI-based diagnosis.
✓ Sample Preparation ✓ Native Digital Imaging ✓ AI Analysis ✓ Reporting
From Biopsy to Treatment Decision
LIMAA provides the complete diagnostic chain: Hardware + Reagents + Software.
Biopsy
The process starts at the tissue sample – not at the glass slide.
Sample
Preparation
The process starts at the tissue sample — not at the glass slide.
Downstream
Workflow
The process starts at the tissue sample — not at the glass slide.
Tissue-preserving Imaging
Native digital imaging through
light-sheet microscopy.
AI-Supported Data Analysis
Automated analysis through LIMAA's intelligent software.
Personalized Diagnosis & Therapy
Results delivered to the tumor board, molecular pathology, and treating physicians.
~15 min
per Sample, End-to-End, 120 Biopsies in Parallel
Proof in Numbers
The world's first fully automated end-to-end solution for digital histopathology
500
Virtual slides in 8 min.
≥50%
faster time-to-result
100%
tissue preservation for successive molecular runs
3
patents submitted
61 Mrd. €
total addressable market 2030
70–99%
gross margin on reagents
1,80 €
costs per sample
Why the Difference Matters
A true end-to-end platform changes not only the viewer, but the entire flow of information. Competitors primarily digitize pathology.
LIMAA automates and digitizes histopathology as a continuous process.
Fewer
interfaces
Less variance between preparation, imaging and analysis.
Automation before
the scan
Value is created already in reagents, processing and native imaging.
Superior
dataset
3D/native digital imaging preserves more context than pure 2D slide digitization.
Scalable
workflow
Standardized output for AI, reporting and laboratory integration.
COMMITTED FOR THE FUTURE OF PATHOLOGY
